Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Mar 21, 2023 1:00pm
129 Views
Post# 35351562

RE:RE:RE:Countdown

RE:RE:RE:CountdownI doubt very much that we would see the same deal, Rosie. That deal was cancelled before the  AGM. But I do question what Midatech, LT and the new investors are up to. It wouldn't surprise me to see another Midatech/Biodexa deal appear. It could be similar to the previous arrangement or it could be a licensing deal, an xB3 asset sale to Biodexa or any of many other possibilities. 

I worry about two larger possibilities:

A) The sale of Bioasis to a private company or near private concern like Biodexa. Bioasis shareholders would receive very little and would very little upside opportunity, especially if xB3 is then sold to a third entity, likely private.

B) Bioasis sells the xB3 Platform and keeps EGF and a few small xB3 licenses like LSDs and/or EGF. These licenses pale in value compared to brain tumours, neurodegenerative diseases, and neuroinflammatory conditions.

In either case, some Bioasis management and BoD would likely join the buyer as with the previous deal. They could benefit despite having destroyed Bioasis.

I don't have any faith that Rathjen can or will make a winner out of Bioasis. I would love to be wrong about that 

jd
<< Previous
Bullboard Posts
Next >>